![](https://webarchive.library.unt.edu/eot2008/20090511131504im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090511131504im_/http://www.cancer.gov/images/spacer.gif)
anti-PD-L1 monoclonal antibody MDX-1105 A fully human monoclonal antibody directed against the protein ligand PD-L1 (Programmed Death-1 Ligand 1) with immunomodulating and potential antineoplastic activities. Anti-PD-L1 monoclonal antibody MDX-1105 binds to PD-L1, blocking its binding to and activation of its receptor, PD-1 (Programmed Death 1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation in chronic infectious disease. PD-L1 is expressed broadly on hematopoietic and parenchymal tissues; PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090511131504im_/http://www.cancer.gov/images/spacer.gif)
Code name: | ![](https://webarchive.library.unt.edu/eot2008/20090511131504im_/http://www.cancer.gov/images/spacer.gif) | MDX-1105 | | ![](https://webarchive.library.unt.edu/eot2008/20090511131504im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090511131504im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090511131504im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090511131504im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090511131504im_/http://www.cancer.gov/images/spacer.gif) |